enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   A large study of more than 2 million people evaluated benefits and risks of GLP-1 agonists. The study showed that GLP-1 agonists reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions [5].

3. Glucagon-like peptide-1 receptor - Wikipedia

   en.wikipedia.org/wiki/Glucagon-like_peptide-1...

   2740 14652 Ensembl ENSG00000112164 ENSMUSG00000024027 UniProt P43220 O35659 RefSeq (mRNA) NM_002062 NM_021332 RefSeq (protein) NP_002053 NP_067307 Location (UCSC) Chr 6: 39.05 – 39.09 Mb Chr 17: 31.12 – 31.16 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and ...

4. Aleniglipron - Wikipedia

   en.wikipedia.org/wiki/Aleniglipron

   Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. [1] It is delivered orally and is in a Phase II trial as of 2023.

5. GLP-1 drugs linked to lower dementia risk, higher risk of ...

   www.aol.com/glp-1-drugs-linked-lower-150000525.html

   The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for weight loss has been greatly increasing. Past studies show there are positive and negative side effects from GLP-1 ...

6. Glucagon-like peptide-1 - Wikipedia

   en.wikipedia.org/wiki/Glucagon-like_peptide-1

   In accordance with the expression of GLP-1 receptor on brainstem and hypothalamus, GLP-1 has been shown to promote satiety and thereby reduce food and water intake. Consequently, diabetic subjects treated with GLP-1 receptor agonists often experience weight loss as opposed to the weight gain commonly induced with other treatment agents. [2] [15]

7. GLP1 poly-agonist peptides - Wikipedia

   en.wikipedia.org/wiki/GLP1_poly-agonist_peptides

   GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.